Page last updated: 2024-08-24

carbenoxolone sodium and Liver Steatosis

carbenoxolone sodium has been researched along with Liver Steatosis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bae, GH; Jung, WH; Kim, CH; Kim, HY; Kim, KY; Kim, TJ; Park, JS; Park, SB; Rhee, SD	1
Hachey, DL; Hasty, AH; Nuotio-Antar, AM	1

Other Studies

2 other study(ies) available for carbenoxolone sodium and Liver Steatosis

Article	Year
Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis. European journal of pharmacology, 2012, Sep-15, Volume: 691, Issue:1-3 Topics: Animals; Apoptosis; Carbenoxolone; Cytokines; Enzyme Inhibitors; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Hep G2 Cells; Humans; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; Sterol Regulatory Element Binding Protein 1; Triglycerides	2012
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:6 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Agouti Signaling Protein; Animals; Atherosclerosis; Blood Pressure; Body Weight; Carbenoxolone; Corticosterone; Energy Metabolism; Fatty Liver; Female; Hyperinsulinism; Hyperlipidemias; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Receptors, LDL	2007

Article

Year

Carbenoxolone prevents the development of fatty liver in C57BL/6-Lep ob/ob mice via the inhibition of sterol regulatory element binding protein-1c activity and apoptosis.

European journal of pharmacology, 2012, Sep-15, Volume: 691, Issue:1-3

Topics: Animals; Apoptosis; Carbenoxolone; Cytokines; Enzyme Inhibitors; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Hep G2 Cells; Humans; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; Sterol Regulatory Element Binding Protein 1; Triglycerides

2012

Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.

American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:6

Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Agouti Signaling Protein; Animals; Atherosclerosis; Blood Pressure; Body Weight; Carbenoxolone; Corticosterone; Energy Metabolism; Fatty Liver; Female; Hyperinsulinism; Hyperlipidemias; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Receptors, LDL

2007